Advent International, a private equity firm based in Boston, Massachusetts, is considering a buyout deal for drugmaker Swedish Orphan Biovitrum.
Advent has approached other buyout firms including Permira in an attempt to lead a consortium for the acquisition of the Swedish biotech firm.
Subscribe to our Newsletter to increase your edge. Don’t worry about the news anymore, through our newsletter you’ll receive weekly access to what is happening. Join 120,000 other PE professionals today.
It is also weighing to bring in sovereign wealth funds for the bid. The talks are at an early stage, and it is not yet clear that they will ultimately lead to a deal, according to the people.
Source: Seeking Alpha
Can’t stop reading? Read more
Investcorp secures $1.25bn for second GP-stakes vehicle
Investcorp secures $1.25bn for second GP-stakes vehicle Investcorp has raised $1.25bn for its...
Blue Owl attracts heavy trading activity as investors focus on private credit outlook
Blue Owl attracts heavy trading activity as investors focus on private credit outlook Blue Owl...
Centurium Capital nears deal for Nestlé’s Blue Bottle Coffee
Centurium Capital nears deal for Nestlé’s Blue Bottle Coffee Centurium Capital Partners is in...